CLINICAL TRIALS PROFILE FOR INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Insulin Susp Isophane Recombinant Human
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00658099 ↗ | Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard® | Completed | Novo Nordisk A/S | 2007-11-01 | This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions. | |
| NCT00665808 ↗ | Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany | Completed | Novo Nordisk A/S | 2007-10-01 | This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The purpose of this NON INTERVENTIONAL OBSERVATIONAL STUDY is to primarily investigate treatment satisfaction when using Levemir® versus Protaphane® in combination with OADs in daily settings. | |
| NCT01122979 ↗ | Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. | Completed | Sanofi | Phase 4 | 2010-07-01 | Primary Objective: >To obtain an estimation for both treatment groups of the proportion of patients that reach the target of HbA1c <= 7% without confirmed nocturnal hypoglycaemia in each treatment group. Secondary Objectives: - Glycemic control, measured by HbA1c and FPG (fasting plasma glucose) at baseline and after each period of treatment. - Incidence of confirmed symptomatic and nocturnal hypoglycemia. - Incidence of confirmed severe hypoglycemia (< 36mg/dL or need of help to recover). >Weight variation for each period of treatment. - Creatinine clearance at baseline and after each period of treatment. - Overall safety: Incidence of adverse events. |
| NCT01680185 ↗ | Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation | Completed | Medical University of Vienna | Phase 3 | 2012-08-01 | The SAPT-NODAT study will test the hypotheses that intensive subcutaneous insulin treatment with short acting insulin, applied continuously through an insulin pump, (i) improves glycemic control, (ii) reduces the prevalence of NODAT and prediabetes, and (iii) offers further β-cell protection, in comparison to the standard of care control group, and the basal insulin treatment group. In the SAPT-NODAT study, we will employ sensor-augmented insulin-pump technology, which performs like a semi-closed loop to prevent hypoglycemic events. Patients in the SAPT-NODAT study will be followed through 24 months post-transplantation. |
| NCT01790438 ↗ | A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes | Completed | Eli Lilly and Company | Phase 3 | 2013-03-01 | The purpose of this study is to compare LY2605541 and human insulin isophane suspension (NPH) using the following measures for participants treated for up to 26 weeks: - Change in participants' overall blood sugar control - The rate of night time low blood sugar episodes - The number of participants that reach blood sugar targets without low night time blood sugar episodes - The total number of low blood sugar episodes reported |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Insulin Susp Isophane Recombinant Human
Condition Name
Clinical Trial Locations for Insulin Susp Isophane Recombinant Human
Trials by Country
Clinical Trial Progress for Insulin Susp Isophane Recombinant Human
Clinical Trial Phase
Clinical Trial Sponsors for Insulin Susp Isophane Recombinant Human
Sponsor Name
